CA2130787A1 - Ursodeoxycholic acid-containing medicament in a liquid administration form - Google Patents

Ursodeoxycholic acid-containing medicament in a liquid administration form

Info

Publication number
CA2130787A1
CA2130787A1 CA002130787A CA2130787A CA2130787A1 CA 2130787 A1 CA2130787 A1 CA 2130787A1 CA 002130787 A CA002130787 A CA 002130787A CA 2130787 A CA2130787 A CA 2130787A CA 2130787 A1 CA2130787 A1 CA 2130787A1
Authority
CA
Canada
Prior art keywords
active agent
ursodeoxycholic acid
administration form
infants
liquid administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002130787A
Other languages
French (fr)
Other versions
CA2130787C (en
Inventor
Josef Olaf Widauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medichemie AG
Original Assignee
Medichemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medichemie AG filed Critical Medichemie AG
Publication of CA2130787A1 publication Critical patent/CA2130787A1/en
Application granted granted Critical
Publication of CA2130787C publication Critical patent/CA2130787C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The active agent ursodeoxycholic acid has proved therapeutically active in infants, inter alia for the treatment of cholestatic hepatic diseases. A problem when administering this active agent, a bile acid, to infants is its extreme bitterness. As a result of the present invention a taste-acceptable, liquid administration form for ursodeoxycholic acid with an adequately high active agent concentration is described. The liquid to be ingested is a suspension prepared accompanied by the addition of a swelling and/or thickening agent, which contains the active agent mainly in fine crystalline form as the disperse phase and only in a much smaller proportion dissolved in the aqueous dispersant. A remaining residual bitterness can be additionally masked by the addition of .beta. -cyclodextrin or suitable taste correcting agents.
CA002130787A 1993-08-30 1994-08-24 Ursodeoxycholic acid-containing medicament in a liquid administration form Expired - Fee Related CA2130787C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH256793 1993-08-30
CH2567/93-2 1993-08-30

Publications (2)

Publication Number Publication Date
CA2130787A1 true CA2130787A1 (en) 1995-03-01
CA2130787C CA2130787C (en) 2006-12-05

Family

ID=4236712

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002130787A Expired - Fee Related CA2130787C (en) 1993-08-30 1994-08-24 Ursodeoxycholic acid-containing medicament in a liquid administration form

Country Status (8)

Country Link
US (1) US5534505A (en)
EP (1) EP0640344B1 (en)
JP (1) JP3631782B2 (en)
AT (1) ATE171874T1 (en)
CA (1) CA2130787C (en)
DE (1) DE59407041D1 (en)
DK (1) DK0640344T3 (en)
ES (1) ES2121599T3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2208497A1 (en) 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
ID29632A (en) * 1998-07-24 2001-09-06 Seo Hong Yoo MAKING DOSE SHAPES OF WATER-BASED SOLID SOLUTIONS WITH BED ACIDS
CN100558407C (en) * 2000-02-04 2009-11-11 柳署弘 Preparation contains the clear aqueous solution dosage form of bile acid
DK1147779T3 (en) * 2000-04-20 2006-09-25 Bioprogress Spa Process for the preparation of pharmaceutical compositions containing ursodeoxycholic acid in soluble form
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
JP4947977B2 (en) * 2003-10-31 2012-06-06 わかもと製薬株式会社 Reversible thermogelling aqueous composition
DE602005020796D1 (en) * 2004-07-22 2010-06-02 Bend Res Inc TASTE-COATING FORMULATION WITH A RETARDANT AGGREGATE FORMULATION AND / OR QUICKLY SOLUBLE CYCLODEXTRIN
EP1789057B1 (en) * 2004-08-30 2010-02-24 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
EP1809330B1 (en) * 2004-10-15 2011-04-27 Seo Hong Yoo Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin
CA2585471A1 (en) * 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
JP2010503667A (en) * 2006-09-15 2010-02-04 ホン ユー，ソ Bile preparation for colorectal disease
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
ES2633766T3 (en) 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver diseases
US10016357B2 (en) * 2012-03-22 2018-07-10 The Beauty Factory, Llc Personal lubricants
US10674867B2 (en) 2013-06-21 2020-06-09 Dode S.A Foldable container
WO2016019066A1 (en) * 2014-07-29 2016-02-04 University Of Tennessee Research Foundation Composition and method for treating liver disease
US20220378803A1 (en) 2019-11-22 2022-12-01 Shilpa Medicare Ltd Injectable compositions of ursodeoxycholic acid
CN115068418B (en) * 2022-07-20 2022-10-28 奥信阳光(北京)药业科技有限公司 Ursodeoxycholic acid oral solution and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639597A (en) * 1968-02-02 1972-02-01 Merck & Co Inc Pharmaceutical compositions containing cholanic acid conjugates
DE2757641C2 (en) * 1977-12-23 1980-03-06 Rowa Ltd., Bantry, Cork (Irland) Use of cis- (33Ä-trimethylcyclohexanol for the treatment of biliary diseases
JPS5522616A (en) * 1978-08-04 1980-02-18 Tokyo Tanabe Co Ltd Bile acid inclusion compound and injection containing the same
US4264583A (en) * 1979-07-25 1981-04-28 The Procter & Gamble Company Gallstone dissolution compositions and method
JPS62153220A (en) * 1985-12-27 1987-07-08 Tokyo Tanabe Co Ltd Water-based bile acid agent for internal use
IT1245889B (en) * 1991-04-12 1994-10-25 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS FOR ORAL USE GAS RESISTANT CONTAINING SALTS OF BILE ACIDS.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2208497A1 (en) 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient

Also Published As

Publication number Publication date
EP0640344A1 (en) 1995-03-01
US5534505A (en) 1996-07-09
EP0640344B1 (en) 1998-10-07
DE59407041D1 (en) 1998-11-12
CA2130787C (en) 2006-12-05
JP3631782B2 (en) 2005-03-23
JPH0782150A (en) 1995-03-28
DK0640344T3 (en) 1999-07-05
ATE171874T1 (en) 1998-10-15
ES2121599T3 (en) 1998-12-01

Similar Documents

Publication Publication Date Title
CA2130787A1 (en) Ursodeoxycholic acid-containing medicament in a liquid administration form
US4711906A (en) Liquid diclofenac preparations
ZA200201904B (en) Topical suspension formulations containing ciprofloxacin and dexamethasone.
UA73954C2 (en) Levosimendan-containing solution for pharmaceutical use, particularly for intravenous administration
RU2001101892A (en) TESTOSTERONE DERIVATIVE
ATE171952T1 (en) PARATHORMONE FRAGMENTS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM
JPH0228121A (en) Transmucosal absorbefacient and pernasal administering agent using the same absorbefacient
DE2818586C2 (en)
US4252797A (en) Corticosteroid calcium compositions and treatment of rheumatic diseases therewith
US20220378803A1 (en) Injectable compositions of ursodeoxycholic acid
US4837211A (en) Spironolactone composition
US5955456A (en) Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol
US3144387A (en) Anti-inflammatory compositions
WO1998043643A1 (en) Aqueous acyclovir solution preparations
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases
DE3942142A1 (en) STABILIZATION OF GLYCOSYLATED T-PA
JPS6169721A (en) Antimycotic composition
DD238921A5 (en) METHOD FOR PRODUCING A CONTRAZEPTIVE SYNERGISTIC COMPOSITION
DE2443431A1 (en) ANTIARTHRITIC AGENT
DE3942143A1 (en) T-PA PRO STABILIZATION
KR950702528A (en) N ^ G-monomethyl-L (L) -arginine hydrogen chloride derivatives and their use in the treatment of septic shock, (N ^ G-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK)
CN1190581A (en) Complex rifampin injection
US3322627A (en) Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor
RU2805311C1 (en) Injectable compositions based on ursodeoxycholic acid
JPH11139970A (en) Oral solution

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130826